Homocysteine levels in newly admitted schizophrenic patients

Journal of Psychiatric Research

Volumn 38, Issue 4, 2004, Pages 413-416

  Applebaum, Julia ^a   Shimon, Hady ^a   Sela, Ben Ami ^b   Belmaker, R H ^a   Levine, Joseph ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

MTHFR; Neurotoxicity; Schizophrenia; Serum homocysteine

Indexed keywords

HOMOCYSTEINE;

ADULT; ARTICLE; CONTROLLED STUDY; EMPLOYEE; FEMALE; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITION; POPULATION RESEARCH; PRIORITY JOURNAL; SCHIZOPHRENIA; SCREENING; SMOKING;

EID: 2942566274     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2004.01.003     Document Type: Article

References (37)

1. Antun F.T., Burnett G.B., Cooper A.J., Daly R.J., Smythies J.R., Zealley A.K. The effects of L-methionine (without MAOI) in schizophrenia. Journal of Psychiatric Research. 8:1971;63-71
2. Araki A., Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography. 422:1987;43-52
3. Arinami T., Yamada N., Yamakawa-Kobayashi K., Hamaguchi H., Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. American Journal of Medical Genetics. 74:1997;526-528
4. Bleich S., Junemann A., Von Ahsen N., Lausen B., Ritter K., Beck G., et al. Homocysteine and risk of open-angle glaucoma. Journal of Neural Transmission. 109:2002;1499-1504
5. Catts V.S., Catts S.V. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophrenia Research. 41:2000;405-415
6. Cohen S.M., Nichols A., Wyatt R., Pollin W. The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biological Psychiatry. 8:1974;209-225
7. Cortese C., Motti C. MTHFR gene polymorphism, homocysteine and cardiovascular disease. Public Health Nutrition. 4:2001;493-497
8. Dimitrova K.R., DeGroot K.W., Suyderhoud J.P., Pirovic E.A., Munro T.J., Wieneke J., et al. 17-β estradiol preserves endothelial cell viability in an in vitro model of homocysteine-induced oxidative stress. Journal of Cardiovascular Pharmacology. 39:2002;347-353
9. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences. 98:2001;6917-6922
10. Godfrey P.S., Toone B.K., Carney M.W., Flynn T.G., Bottiglieri T., Laundy M., et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 336:1990;392-395
11. Grigoriadis S., Seeman M.V. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Canadian Journal of Psychiatry. 47:2002;437-442
12. Ho P.I., Collins S.C., Dhitavat S., Ortiz D., Ashline D., Rogers E., et al. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. Journal of Neurochemistry. 78:2001;249-253
13. Ho P.I., Ortiz D., Rogers E., Shea T.B. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. Journal of Neuroscience Research. 70:2002;694-702
14. Huang R.F., Huang S.M., Lin B.S., Wei J.S., Liu T.Z. Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells. Life Sciences. 68:2001;2799-2811
15. James S.J., Melnyk S., Pogribna M., Pogribny I.P., Caudill M.A. Elevation in S-adenosylhomocysteine and DNA hypomethylation: Potential epigenetic mechanism for homocysteine-related pathology. Journal of Nutrition. 132:2002;2361S-2366S
16. Jarskog L.F., Gilmore J.H., Selinger E.S., Lieberman J.A. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biological Psychiatry. 48:2000;641-650
17. Joober R., Benkelfat C., Lal S., Bloom D., Labelle A., Lalonde P., et al. Association between the methylenetetrahydrofolate reductase 677C. → T missense mutation and schizophrenia Molecular Psychiatry. 5:2000;323-326
18. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., et al. Estrogen - a potential treatment for schizophrenia. Schizophrenia Research. 48:2001;137-144
19. Kunugi H., Fukuda R., Hattori M., Kato T., Tatsumi M., Sakai T., et al. C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. Molecular Psychiatry. 3:1998;435-457
20. Levine J., Stahl Z., Sela B.A., Gavendo S., Ruderman V., Belmaker R.H. Elevated homocysteine levels in young male patients with schizophrenia. American Journal of Psychiatry. 159:2002;1790-1792
21. Lipton S.A., Kim W.K., Choi Y.B., Kumar S., D'Emilia D.M., Rayudu P.V., et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proceedings of the National Academy of Sciences. 94:1997;5923-5928
22. Madsen J.S., Kristensen S.R., Klitgaard N.A., Bladbjerg E.M., Abrahamsen B., Stilgren L., et al. Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. American Journal of Obstetrics and Gynecology. 187:2002;33-39
23. Mattson M.P., Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends in Neuroscience. 26:2003;137-146
24. Moore P., El-sherbeny A., Roon P., Schoenlein P.V., Ganapathy V., Smith S.B. Apoptotic cell death in the mouse retinal ganglion cell layer is induced in vivo by the excitatory amino acid homocysteine. Experimental Eye Research. 73:2001;45-57
25. O'Callaghan P., Meleady R., Fitzgerald T., Graham I. Smoking and plasma homocysteine. European Heart Journal. 23:2002;1580-1586
26. Pollin W., Cardon P., Kety S. Effect of amino acid feedings in schizophrenic patients treated with iproniazid. Science. 133:1961;104-105
27. Regland B., Germgard T., Gottfries C.G., Grenfeldt B., Koch-Schmidt A.C. Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis. Journal of Neural Transmission. 104:1997;931-941
28. Regland B., Johansson B.V., Grenfeldt B., Hjelmgren L.T., Medhus M. Homocysteinemia is a common feature of schizophrenia. Journal of Neural Transmission. 100:1995;165-169
29. Sachdev P.S., Valenzuela M., Wang X.L., Looi J.C., Brodaty H. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology. 58:2002;1539-1541
30. Schneede J., Refsum H, Ueland P.M. Biological and environmental determinants of plasma homocysteine. Seminars in Thrombosis and Hemostasis. 26:2000;263-279
31. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New English Journal of Medicine. 346:2002;476-483
32. Stahl Z, Levine J, Belmaker RH, Epidemiology and life style determinants of elevated homocysteine in schizophrenic patients. (submitted)
33. Susser E., Brown A.S., Klonowski E., Allen R.H., Lindenbaum J. Schizophrenia and impaired homocysteine metabolism: a possible association. Biological Psychiatry. 44:1998;141-143
34. Virgos C., Martorell L., Simo J.M., Valero J., Figuera L., Joven J., et al. Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Neuroreport. 10:1999;2035-2038
35. Wei J., Hemmings G.P. Allelic association of the MTHFR gene with schizophrenia. Molecular Psychiatry. 4:1999;115-116
36. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 15:2001;287-310
37. Zandi P.P., Carlson M.C., Plassman B.L., Welsh-Bohmer K.A., Mayer L.S., Steffens D.C., et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 288:2002;2123-2129